8:16 AM
Mar 30, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Allecra reports Phase II data for AAI101 combo to treat cUTI

Allecra Therapeutics GmbH (Lörrach, Germany) reported top-line data from the Phase II CACTUS trial in 45 hospitalized adults with complicated urinary tract infections (cUTIs), including pyelonephritis, showing that AAI101 in combination with cefepime was well tolerated. Patients in the double-blind trial received 500 or 750 mg IV AAI101 plus cefepime...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >